Project Grant R21HD114073

Award Date 8/13/24
Completion Date 7/31/26
Dollars Obligated $426K
Federal Grant Program
93.865
Assistance Type
Project Grant
Place of Performance
Winston-Salem, NC 27157, USA
Similar Awards
This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on investigating the role of Plasminogen Activator Inhibitor 1 (PAI1) as a potential therapeutic target for maternal endothelial dysfunction in preeclampsia. The $806,978 award, with a performance period from August 1, 2025 to June 30, 2030, will support research at Yale University to gain insights into maternal...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) provides $485,925 to the University of Massachusetts Boston to develop novel antioxidant compounds for treating preeclampsia, a life-threatening pregnancy complication. The primary goal is to design and synthesize cationic hydrazone antioxidants that can target mitochondria to reduce oxidative stress, improve...
This Project Grant award from the Department of Health and Human Services National Institutes of Health National Institute of Child Health and Human Development provides $769,916 to Emergent Biotechnologies LLC for research into a novel therapy for preeclampsia. The funding supports Phase 1 of developing and characterizing a handle region peptide as an innovative treatment for preeclampsia under the Child Health and Human Development Extramural Research program (CFDA 93.865). Phase 1 work will...
This Project Grant award, valued at $148,880 and funded by the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research), supports research to investigate the long-term effects of B cells in preeclampsia (PE) on offspring. The University of Mississippi Medical Center (UMMC) will isolate B cells from the placentas of PE patients and adoptively transfer them into pregnant rats to examine the impact on blood pressure, immune...
This $550,000 Project Grant award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development and validation of a non-invasive, multiplex blood test for the early detection of preeclampsia, a serious pregnancy complication. The project aims to advance the detection of vascular dysfunction, particularly preeclampsia, by optimizing a blood test that targets disease-inducing signaling proteins on the surface of...
This $658,418 federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports a randomized, double-blind clinical study to investigate the cardiac effects of mineralocorticoid receptor antagonism in women with prior preeclampsia who have developed chronic hypertension. The study aims to assess whether MR blockade can promote favorable cardiac remodeling and improve coronary microvascular function, independent of blood...
This Cooperative Agreement award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $750,962 in funding to the University of Mississippi Medical Center (UMMC) to conduct research on the causes of sex differences in male and female offspring born from inflammation-mediated hypertensive pregnancy, with a focus on preeclampsia (PE). The research aims to elucidate novel mechanisms linking placental ischemia and...
This Project Grant award of $2,559,308, funded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports a study on the impact of severe pre-eclampsia on heart function in women from diverse racial backgrounds. The study, titled "SHEPREG: Study of Heart Function in Pre-Eclampsia During and After Pregnancy", will evaluate heart function at delivery and 6-12 months postpartum. It aims to describe the cardiomyopathic genetic profile of the...
This federal Project Grant award of $648,102 from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), supports research to investigate the role of the GPR173 receptor and its associated signaling pathway in regulating plasma volume expansion during pregnancy. The key research objectives are to use siRNA-mediated knockdown approaches in pregnant rats to evaluate the...
This $151,040 Project Grant award from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) supports research into the effects of rare damaging mutations in TGFB latent complex proteins found in preeclamptic placentas. The project aims to investigate how these mutations impact TGF-beta signaling, extracellular matrix integrity, and the migration, invasion, and...

APELIN RECEPTOR AXIS AND LONG-TERM CONSEQUENCES OF PREECLAMPSIA - SUMMARY PREECLAMPSIA (PE) IS A HYPERTENSIVE DISORDER OF PREGNANCY THAT OCCURS IN 5-7% OF ALL PREGNANCIES. WOMEN EXPOSED TO PE ARE MORE LIKELY TO DEVELOP CARDIOVASCULAR AND SUBCLINICAL CEREBROVASCULAR EVENTS LATER IN LIFE. RECENT STUDIES SUGGEST AN ALARMING TREND THAT WOMEN WITH A HISTORY OF PE OFTEN EXPERIENCE PRONOUNCED SUBJECTIVE COGNITIVE AND PSYCHOLOGICAL DYSFUNCTION THAT SIGNIFICANTLY ALTERS THEIR QUALITY OF LIFE. ALTHOUGH THE EXACT MECHANISMS OF THIS SUBCLINICAL DISEASE ARE NOT WELL UNDERSTOOD, ENDOTHELIAL DYSFUNCTION AND INFLAMMATION ARE IMPLICATED IN THE PATHOGENESIS OF THE CEREBROVASCULAR AND COGNITIVE SYNDROME AFTER PE. THE APELINERGIC SYSTEM, CONSISTING OF APELIN, ELABELA (ELA), AND THE APELIN RECEPTOR (APJ), IS A NOVEL THERAPEUTIC PATHWAY IN PREECLAMPSIA. OUR STUDIES DEMONSTRATED THAT APELIN HAS ANTI-HYPERTENSIVE AND RENO-PROTECTIVE EFFECTS. HOWEVER, APELIN ALSO REDUCES BRAIN EDEMA, INFLAMMATION AND OXIDATIVE STRESS IN MODELS OF TRANSIENT MODEL OF FOCAL CEREBRAL ISCHEMIA, ISCHEMIA-REPERFUSION, AND STROKE SUGGESTING ITS POTENTIAL AS NEUROPROTECTOR. STUDIES PROPOSED IN THIS APPLICATION ARE BASED ON THE CLINICAL EVIDENCE SUGGESTING A LINK BETWEEN PREECLAMPSIA AND VASCULAR DEMENTIA- LIKE SYNDROME EXPERIENCED BY WOMEN YEARS AFTER THE EXPOSURE TO PE. OUR STUDIES WILL ESTABLISH THE NEUROPROTECTIVE ACTIONS OF APELINERGIC AXIS ON LONG-TERM CEREBROVASCULAR CONSEQUENCES OF PREECLAMPSIA. THE ESTABLISHED AND WELL-CHARACTERIZED MODELS OF NORMAL PREGNANCY AND PREECLAMPSIA ARE READILY AVAILABLE IN OUR LABORATORY AND WILL BE USED FOR THIS PROJECT. THESE STUDIES WILL IMPROVE OUR UNDERSTANDING OF THE PROTECTIVE ROLE OF APELIN/APJ AXIS IN PREECLAMPSIA.

Posted 8/13/24